Skip to main content
Brightgene Bio-Medical Technology Co., Ltd. logo

Brightgene Bio-Medical Technology Co., Ltd. — Investor Relations & Filings

Ticker · 688166 ISIN · CNE100003PR1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 996 across all filing types
Latest filing 2026-05-26 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688166

About Brightgene Bio-Medical Technology Co., Ltd.

https://www.bright-gene.com/

Brightgene Bio-Medical Technology Co., Ltd. is a research-driven pharmaceutical enterprise specializing in the development and manufacturing of high-end generic drugs and innovative medicines. The company focuses on complex active pharmaceutical ingredients (APIs) and finished dosage forms across therapeutic areas such as oncology, anti-infectives, cardiovascular diseases, and metabolic disorders. Brightgene leverages advanced technology platforms, including microbial fermentation, high-end chemical synthesis, and specialized drug delivery systems, to produce high-barrier pharmaceutical products. Its portfolio includes a range of antifungal, antiviral, and immunosuppressant agents. The company maintains a global supply chain, providing high-quality pharmaceutical solutions to international markets while adhering to rigorous quality standards and regulatory requirements.

Recent filings

Filing Released Lang Actions
关于董事、董事会秘书离任的公告
Board/Management Information Classification · 92% confidence The document is an official announcement detailing the resignation of a board member and board secretary, specifying roles, effective dates, and transitional arrangements. It clearly concerns changes in the company’s board of directors and senior management. This matches the Board/Management Information category.
2026-05-26 Chinese
关于“博瑞转债”赎回结果暨股份变动的公告
Share Issue/Capital Change Classification · 87% confidence The document is a corporate announcement by 博瑞生物医药（苏州）股份有限公司 detailing the redemption of its convertible bonds (“博瑞转债”), the redemption results (quantities, amounts, dates), and the consequent share capital changes (conversion of bonds to shares, updated share counts). This is a formal notice of a capital structure change — specifically, issuance of new shares via bond conversion and redemption of the bonds. According to the filing definitions, this fits “Share Issue/Capital Change (Code: SHA)” rather than a casual update or repurchase. It is not a simple report publication or an earnings release, but an official announcement of share capital changes. Hence, the correct classification is SHA.
2026-05-22 Chinese
关于实施“博瑞转债”赎回暨摘牌的最后一次提示性公告
Capital/Financing Update Classification · 85% confidence The document is a corporate announcement from BrightGene (博瑞生物医药) concerning the mandatory redemption (“赎回”) of its convertible bonds (‘博瑞转债’) and the subsequent removal (摘牌) of that bond from the Shanghai Stock Exchange. It contains detailed terms, timeline and procedures for the bond redemption—a change in the company's capital structure—rather than a general regulatory filing or stock delisting notice. Hence it best fits “Capital/Financing Update” (CAP).
2026-05-20 Chinese
关于实施“博瑞转债”赎回暨摘牌的第八次提示性公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by the company’s board concerning the early redemption (“call”) of its convertible bonds (“博瑞转债”) and the subsequent delisting of those bonds on the exchange. It details redemption dates, prices, procedures, and delisting schedules – all matters related to the company’s financing instruments and capital structure. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report, stock delisting (which refers to equity), or other categories.
2026-05-19 Chinese
关于重新向香港联合交易所有限公司递交H股发行及上市的申请并刊发申请资料的公告
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement (‘公告’) informing investors of the company’s resubmission of its application for an H-share issuance and listing on the Hong Kong Stock Exchange, including links to the application materials. This constitutes an announcement of a new share issuance and change in capital structure. According to the definitions, this falls under Share Issue/Capital Change (SHA).
2026-05-18 Chinese
关于召开2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 75% confidence The document is a regulatory announcement (公告) by the company providing logistics for a Q1 2026 performance explanation meeting (业绩说明会). It does not contain financial statements or presentation materials itself, nor is it the release of the actual quarterly report (which was already published on April 30). It is not an earnings release, transcript, or investor slide deck, so it falls under the general “Regulatory Filings” category as a fallback for miscellaneous compliance announcements.
2026-05-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.